A trial evaluating cabazitaxel versus docetaxel rechallenge for the treatment of metastatic castrate refractory prostate cancer, previously treated with docetaxel at inception of primary hormone therapy
ISRCTN | ISRCTN16465571 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN16465571 |
EudraCT/CTIS number | 2012-003835-40 |
Secondary identifying numbers | 13741 |
- Submission date
- 26/03/2013
- Registration date
- 26/03/2013
- Last edited
- 21/06/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Contact information
Mr Nick Martin
Scientific
Scientific
Cancer Research UK Clinical Trials Unit
Institute for Cancer Studies
Edgbaston
Birmingham
B15 2TT
United Kingdom
CANTATA@trials.bham.ac.uk |
Study information
Study design | Randomised; Interventional; Design type: Treatment |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
Scientific title | A multicentre, phase II randomised controlled trial evaluating cabazitaxel versus docetaxel rechallenge for the treatment of metastatic castrate refractory prostate cancer, previously treated with docetaxel at inception of primary hormone therapy |
Study acronym | CANTATA |
Study objectives | This study compares the safety and levels of activity of cabazitaxel versus docetaxel re-challenge in patients with metastatic castrate refractory prostate cancer who have been previously exposed to combined docetaxel and androgen deprivation as first-line treatment for advanced prostate cancer. The difference between treatment arms in terms of the number of patients who have a clinical event (clinical progression or death) will provide the evidence whether the levels of activity of cabazitaxel warrant further investigation in a phase III trial. |
Ethics approval(s) | Liverpool Central - North West NRES Committee, 10/12/2012, ref: 12/NW/0792 |
Health condition(s) or problem(s) studied | Prostate cancer |
Intervention | Patients will be randomised to one of the following two treatments (plus 10mg prednisolone daily in either regimen): 1. Cabazitaxel 25mg/m2 3 weekly plus prednisolone for up to 10 cycles 2. Docetaxel 75mg/m2 3 weekly plus prednisolone for up to 10 cycles Follow Up Length: 24 month(s) |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase II |
Drug / device / biological / vaccine name(s) | Cabazitaxel, docetaxel |
Primary outcome measure | Clinical progression-free survival (CPFS) |
Secondary outcome measures | No secondary outcome measures |
Overall study start date | 07/03/2013 |
Completion date | 29/04/2016 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Male |
Target number of participants | Planned Sample Size: 138; UK Sample Size: 138; Description: Target recruitment is 138 patients in total, with 69 patients per arm. |
Total final enrolment | 15 |
Key inclusion criteria | 1. Diagnosis of histologically proven prostate adenocarcinoma, that is castrate refractory 2. Previously treated with up to 6 cycles of Docetaxel at the same time (defined as commencing within 3 months) as instigation of primary hormone therapy. 3. Confirmed biochemical, radiological or clinical progression. 4. Metastatic disease 5. Male and female, aged 18 or over 6. WHO performance status grade 0 to 2 7. Adequate organ function as evidenced by: 7.1. ANC >1.5 x109/L 7.2. WBC >3.0 x109/L 7.3. Haemoglobin >10g/dL 7.4. Platelet count > 100 x10^9L 7.5. Total bilirubin <1.0 xULN 7.6. AST/ ALT <1.5 xULN 7.7. GFR >30ml/min (calculated by EDTA clearance, 24h urine collection, or Cockcroft-Gault) 8. Available for long-term follow up 9. Patients written informed consent |
Key exclusion criteria | 1. Prior systemic therapy with other chemotherapy drugs 2. Metastatic brain disease or leptomeningeal disease 3. Patients with bilirubin equal to or greater than 1.0 xULN 4. Previous extensive palliative radiotherapy to bone marrow, e.g. hemibody radiotherapy 5. Active grade >=2 peripheral neuropathy (NCI CTC v 4) 6. Active infection requiring systemic antibiotic or antifungal medication 7. Patients with reproductive potential not implementing accepted and effective method of contraception |
Date of first enrolment | 07/03/2013 |
Date of final enrolment | 12/01/2016 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
The Queen Elizabeth Hospital
Edgbaston
Birmingham
B15 2TH
United Kingdom
Birmingham
B15 2TH
United Kingdom
Sponsor information
University of Birmingham (UK)
University/education
University/education
Edgbaston
Birmingham
B15 2TT
England
United Kingdom
Website | http://www.birmingham.ac.uk/researchsupportgroup |
---|---|
https://ror.org/03angcq70 |
Funders
Funder type
Industry
Aventis Pharma Ltd T/A Sanofi-Aventis
No information available
Cancer Research UK (UK)
Private sector organisation / Other non-profit organizations
Private sector organisation / Other non-profit organizations
- Alternative name(s)
- CR_UK, Cancer Research UK - London, CRUK
- Location
- United Kingdom
Results and Publications
Intention to publish date | 31/12/2017 |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Stored in repository |
Publication and dissemination plan | Results of this trial will be submitted for publication in a peer-reviewed journal. The manuscript will be prepared by the Trial Management Group (TMG) and authorship will be determined by mutual agreement. |
IPD sharing plan | The datasets generated during and/or analysed during the current study will be stored in a publically available repository in 2017. Repository : European Medicines Agency (EMA)’s European Clinical Trial Database, EudraCT V10. URL : http://eudract.ema.europa.eu |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Basic results | 21/06/2019 | No | No | ||
HRA research summary | 28/06/2023 | No | No |
Editorial Notes
21/06/2019: Added clinicaltrialsregister.eu link to basic results (scientific). Added total final enrollment.
20/02/2017: The overall trial end date was changed from 12/02/2016 to 29/04/2016.
14/11/2016: The overall trial end date was changed from 30/06/2015 to 12/02/2016.